Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04136309 food effect study in healthy subjects
NCT02598206Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PF-04136309 in pancreatic cancer (PC) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve from time Zero to Extrapolated Infinite Time at 96 hours and Maximum Plasma Concentration at 96 hours. Started Dec 2015; status: completed.
02
Drugs
PF-04136309
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02598206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598206.